FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 331:1223-1225 November 3, 1994 Number 18 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article PubMed Citation

In February 1994 the Data and Safety Monitoring Board of the National Institute of Allergy and Infectious Diseases recommended the interruption of a clinical trial designed to determine whether the administration of zidovudine to pregnant women infected with the human immunodeficiency virus (HIV) and to their newborns could reduce the rate of vertical viral transmission. Given the responsibilities of the Data and Safety Monitoring Board, there was no alternative. The difference in the rate of transmission between those receiving zidovudine and those receiving placebo was statistically significant (P = 0.00006). Women who received zidovudine had a transmission rate of 8.3 . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Peckham, C., Gibb, D. (1995). Mother-to-Child Transmission of the Human Immunodeficiency Virus. NEJM 333: 298-303 [Full Text]  
• (1995). Management of HIV Infection During Pregnancy: New Options, New Questions. AIDS Clin Care 1995: 1-1 [Full Text]  
• Hoffman, C. A., Munson, R., Thea, D. M., De Roo, A., Colebunders, R., Bayer, R. (1995). Ethical Issues in the Use of Zidovudine to Reduce Vertical Transmission of HIV. NEJM 332: 891-892 [Full Text]